Here at ODMA we aim to keep you up to date with all of the latest innovations and medical news from the industry. As a part of this, we would like to share the article below from the Look for Life Foundation (formerly Genetic Eye Foundation) whose Chairman Professor Minas Coroneo is one of the keynote speakers at ODMA17 www.odma2017.com.au/conference
If you are not aware, the Look for Life Foundation is a not-for-profit organisation dedicated to promoting awareness, diagnosis and support for patients with genetic eye conditions. To use their own words from their website “The foundation has made significant contributions to eye health research in Australia, including contributions to bionic eye research, the creation of the largest database of retinal dystrophy family trees in Australia as well as research into stem cell deficiency in the eye”.
This is a letter to the Foundation from the Chairman of Pixium Vision – Bernard Gilly.
Pixium Vision, is a company focused on restoring vision for people who have lost their sight. In 2010 there were approximately 40 -45 million people who were completely blind and for these patients t, ere is currently no treatment available.
Pixium is developing Vison Restoration Systems, which aim to provide blind patients with visions as close to possible as normal. Each VRS comprises three components, and is associated with a
surgical procedure and a rehabilitation program. It is composed of a retinal implant attached to the retinal in the eye to stimulate nerve cells; a portable visual interface in the form of pair of glasses with an integrated mini-camera to capture visual information, and a pocket computer to convert the visual information into electrical signals transmitted to the implant to stimulate the retinal cells and create “vision”. To start, Pixium Vision intends to commercialise its VRS for retinitis pigmentosa (RP).
Age-related macular degeneration (AMD) will follow. Theses irreversible pathologies aﬀect people who had normal vision until the onset of symptoms. It is estimated that between 15,000 and 20,000 new RP patents lose their sight each year in Europe and in the United States. AMD aﬀects many more people in Europe and the US with more than 350,000 to 400,000 new patents expected to lose their sight each year. Clinical studies for IRIS® started in June 2013 in a number of clinical centres in Europe.
So far, patients are tolerating the implant well, the devices are functional after implantation, and improvements in the visual perception of blind patents have been observed. PRIMA is a preclinical development and the company began clinical trials in Europe in 2016. Recent IPO was an important milestone in Pixium Vision’s development.
The company will use the proceeds raised from the IPO to support the clinical development and commercial launch of its IRIS® VRS in Europe and the Unites States, as well as the development of the PRIMA VRS to the point of its commercialisation in Europe. IRIS® and then with PRIMA, Pixium Vision will be in a unique positon to significantly contribute to the restoration of vision for people who have lost their sight, enabling them to have more independence and to play a greater role in society.
For more information of Look for Life Foundation – click here
For more information regarding Pixium Vision – click here